Researchers at ETH Zurich have identified a potential new path for treating Alzheimer’s disease by targeting a specific enzyme, GRK2. According to findings published in the journal Cell Reports Medicine, the team developed a chemical compound, referred to as “Compound 10,” which inhibits the formation of GRK2 aggregates that damage nerve cells and contribute to dementia progression.
How does the new compound work?
The research, led by Professor of Molecular Pharmacology Ursula Quitterer at ETH Zurich, focuses on the bodily enzyme GRK2. In healthy cells, this regulatory protein helps cells respond to stress. However, Quitterer’s team discovered that in dementia patients, an inactivated form of GRK2 accumulates in the brain. According to the research, these aggregates block the pores of mitochondria—the cell’s “powerhouses”—leading to energy deficits and cellular stress.
Compound 10 prevents these GRK2 molecules from clumping together. By stopping the aggregation, the substance helps mitochondria function effectively and reduces the production of amyloid beta, a protein fragment widely considered a primary driver of Alzheimer’s. This creates a protective effect, slowing the nerve cell death typically associated with the disease.
Why did this research take two decades?
The development of Compound 10 is the culmination of nearly 20 years of work. Quitterer explains that the timeline is largely due to the nature of Alzheimer’s research itself. Because the team was investigating an age-related condition, experiments required the use of older mice, typically aged one and a half to two years. Each experiment required a similarly long duration to produce data, making the process significantly slower than fields like cancer research.
The project began when Quitterer received human brain tissue samples from a colleague at the Ain Shams University Hospital in Cairo. These samples, collected during tumor surgeries from both dementia and non-dementia patients, provided the foundation for the molecular analyses that identified the role of GRK2.
What are the broader effects on health?
Beyond its impact on the brain, Compound 10 showed promise in other areas of physiology during animal testing. According to the research team, mice treated with the compound displayed improved heart function and exhibited anti-ageing effects. For instance, the treated animals showed a reduction in grey hair compared to untreated counterparts. While the primary goal remains addressing Alzheimer’s, these systemic benefits suggest the compound may influence broader cellular ageing processes.
What are the next steps for drug development?
With basic research and patent applications complete, the team at ETH Zurich is now seeking a commercial partner to move the substance toward clinical development. Quitterer notes that because existing medications do not cure the disease, the identification of a new target mechanism like GRK2 is vital for future patient care. The goal is to eventually integrate Compound 10 into existing treatment regimens to improve the quality of life for those living with dementia.
Frequently Asked Questions
- What is Compound 10? It is a chemical substance developed by ETH Zurich researchers that prevents the enzyme GRK2 from forming harmful aggregates in brain cells.
- How does GRK2 affect Alzheimer’s? Inactivated GRK2 forms aggregates that damage mitochondria and promote amyloid beta production, creating a cycle of stress that kills nerve cells.
- Is this treatment currently available? No. The research is currently in the stage of seeking a company to partner with for further drug development.
- Did the study show benefits beyond the brain? Yes, the research team observed improved heart function and anti-ageing effects in mice, such as fewer grey hairs.
Are you interested in the latest breakthroughs in neuroscience? Subscribe to our monthly research newsletter to stay updated on clinical trial progress and emerging medical technologies.
